These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 6804110)

  • 41. Increased incidence of side effects after encainide: a newly developed antiarrhythmic drug.
    Berchtold-Kanz E; Schwarz G; Hust M; Nitsche K; Just H
    Clin Cardiol; 1984 Sep; 7(9):493-7. PubMed ID: 6442223
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia.
    Platia EV; Estes M; Heine DL; Griffith LS; Garan H; Ruskin JN; Reid PR
    Am J Cardiol; 1985 Apr; 55(8):956-62. PubMed ID: 3984883
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Encainide for refractory ventricular tachyarrhythmia.
    Chesnie B; Podrid P; Lown B; Raeder E
    Am J Cardiol; 1983 Sep; 52(5):495-500. PubMed ID: 6193701
    [No Abstract]   [Full Text] [Related]  

  • 44. Efficacy and safety of combination therapy with amiodarone and type I agents for treatment of inducible ventricular tachycardia.
    Jung W; Mletzko R; Manz M; Nitsch J; Lüderitz B
    Pacing Clin Electrophysiol; 1993 Apr; 16(4 Pt 1):778-88. PubMed ID: 7683805
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dose-response range of encainide for benign and potentially lethal ventricular arrhythmias.
    Morganroth J; Pool P; Miller R; Hsu PH; Lee I; Clark DM
    Am J Cardiol; 1986 Apr; 57(10):769-74. PubMed ID: 3083665
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of encainide in supraventricular arrhythmias.
    Pool PE
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():573-7. PubMed ID: 2125835
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals.
    Carey EL; Duff HJ; Roden DM; Primm RK; Wilkinson GR; Wang T; Oates JA; Woosley RL
    J Clin Invest; 1984 Feb; 73(2):539-47. PubMed ID: 6421879
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Acute and long-term antiarrhythmia effect of encainide in chronic atrial extrasystole].
    Thale J; Klein H; Shanks RG; Bender F
    Z Kardiol; 1985 Apr; 74(4):220-7. PubMed ID: 2408392
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Electrophysiologic and clinical effects of oral encainide in paroxysmal atrioventricular node reentrant tachycardia.
    Chimienti M; Li Bergolis M; Moizi M; Salerno JA
    J Am Coll Cardiol; 1989 Oct; 14(4):992-8. PubMed ID: 2507613
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of twice daily with thrice daily administered encainide for benign or potentially lethal ventricular arrhythmias.
    Hohnloser SH; Zabel M; Zehender M; Meinertz T; Just H
    Am J Cardiol; 1989 Jan; 63(1):73-6. PubMed ID: 2462343
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment.
    Bigger JT
    Am J Cardiol; 1990 Feb; 65(8):3D-10D; discussion 68D-71D. PubMed ID: 2106253
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human Electropharmacology of Tocainide, a lidocaine congener.
    Horowitz LN; Josephson ME; Farshidi A
    Am J Cardiol; 1978 Aug; 42(2):276-80. PubMed ID: 685840
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Encainide--an updated safety profile.
    Thomis JA
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():585-94. PubMed ID: 2125837
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia.
    Kuck KH; Kunze KP; Schlüter M; Duckeck W
    Am J Cardiol; 1988 Dec; 62(19):37L-44L. PubMed ID: 3144166
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Encainide. A review of its pharmacological properties and therapeutic efficacy.
    Brogden RN; Todd PA
    Drugs; 1987 Nov; 34(5):519-38. PubMed ID: 3121275
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute intravenous and long-term oral hemodynamic effects of encainide.
    Sami MH
    Am J Cardiol; 1986 Aug; 58(5):25C-30C. PubMed ID: 3092616
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recruitment and baseline description of patients in the Cardiac Arrhythmia Pilot Study. The Cardiac Arrhythmia Pilot Study (CAPS) investigators.
    Am J Cardiol; 1988 Apr; 61(10):704-13. PubMed ID: 2451414
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Encainide: a new antiarrhythmic agent.
    Wehmeyer AE; Thomas RL
    Drug Intell Clin Pharm; 1986 Jan; 20(1):9-13. PubMed ID: 3080301
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and electrophysiologic effects of encainide for atrioventricular nodal reentrant tachycardia.
    Naccarelli GV; Jackman WM; Akhtar M; Rinkenberger RL; Friday KJ; Dougherty AH; Tchou P; Yeung-Lai-Wah JA
    Am J Cardiol; 1988 Dec; 62(19):31L-36L. PubMed ID: 3144165
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Electrophysiological effects of encainide in man].
    Cassagneau B; Calazel J; Puel J; Massabuau P; Miquel JP; Bounhoure JP; Marin T; Narula OS
    Arch Mal Coeur Vaiss; 1984 Jun; 77(6):707-11. PubMed ID: 6431937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.